LAB UPDATE

ST. VINCENT INDIANAPOLIS & WOMEN'S HOSPITALS

BIOTIN INTERFERENCE-NEW CHEMISTRY INSTRUMENTATION

EFFECTIVE DATE: APRIL 30, 2019

Mid America Clinical Laboratories is implementing new chemistry instrumentation across our network. With this change, a number of tests have the potential to be affected by Biotin interference ***when performed within the Hospital Based Laboratory***.

Only those patients (***0.7% of the population***) taking Mega-Dose Biotin Supplements as part of a treatment protocol are affected. However, healthcare providers are encouraged to talk with their patients regarding the use of biotin supplements and the potential interference they can have in obtaining accurate lab work.

It is recommended that supplements be suspended 24 hours prior to collection to minimize the potential of interference. However, those patients that receive biotin therapy intravenously can experience interference for longer periods of time depending on the dose and metabolism of the patient.

The following is a list of tests that are known to demonstrate at least a 10% bias due to biotin interference. Information regarding the biotin interference is included in the MACL Directory of Service order information.

ASSAYS EXPERIENCING FALSE DECREASE	
CKMB	TROPONIN-I
HCG	TSH

Additional details including dose information and references are located on our website at:
http://www.maclonline.com/lab-updates/

Testing of these assays is not affected on the instrumentation located at our Regional Laboratory. If a patient is receiving biotin therapy or patient results are suspected to be impacted by potential biotin interference, request routine testing to be completed at the Regional Laboratory.

If you have any questions, please contact:

Becky Brtva, Chemistry Manager, Mid America Clinical Laboratories – (317) 803-0101
Dianne Griffith, Director, Laboratory Operations, Mid America Clinical Laboratories – (317) 803-0460
Dr. Terence Cudahy, M.D., Medical Director, Mid America Clinical Laboratories – (317) 803-0253